The verdict
Our read at a glance.
Whether glucagon is understood as the approved emergency hormone that raises dangerously low blood sugar (and a diagnostic gut relaxant), distinct from the glucagon-receptor activation built into the new dual and triple agonist obesity drugs.
- The signal
- Decades of use establish injected or nasal glucagon as a fast, effective rescue for severe hypoglycemia, raising blood sugar within minutes when someone cannot safely eat or drink. Newer ready-to-use injectors and the nasal powder work about as well as the old reconstituted kits while being far easier to give correctly in a crisis.
- The unknown
- Little about the rescue use is unsettled. The open frontier runs the opposite direction: how partial, sustained glucagon-receptor activation in dual and triple agonists helps with weight and metabolism without worsening blood-sugar control, which is a different job for the same receptor.
- Our read
- Insulin's mirror image and a genuine emergency drug. Glucagon reliably and quickly raises dangerously low blood sugar by telling the liver to release its stored sugar, and it now comes in needle-free nasal and ready-to-use forms. Read it as an acute rescue (and a procedural gut relaxant), and as the hormone whose receptor the new dual and triple agonist obesity drugs deliberately, and very differently, switch on.
The mechanism
How it works.
Blood sugar is held in a balance between two pancreatic hormones: insulin lowers it, glucagon raises it. When blood sugar falls too low, glucagon binds its receptor on liver cells and tells the liver to break down its stored sugar (glycogen) and make new sugar, pushing blood glucose back up within minutes. As a medicine, a dose of glucagon does this on demand, which is why it is the rescue for severe low blood sugar when someone cannot safely eat, including as a nasal powder that needs no needle. It only works if the liver has sugar in storage, so it can fall short after prolonged fasting or heavy alcohol use. The same receptor, switched on in a partial, steady way, is one of the levers the new dual and triple agonist weight-loss drugs pull, which is a different job from the quick rescue.
Safety & regulatory boundary
The consequential part.
Glucagon commonly causes nausea or vomiting and briefly raises heart rate and blood pressure; it only works if the liver has sugar in storage, so it can fall short after prolonged fasting, heavy alcohol use, or adrenal insufficiency, and it is used cautiously in rare tumors such as pheochromocytoma, insulinoma, and glucagonoma. Because the effect is temporary, the person needs to eat once they are able. It is an approved acute rescue medicine and a diagnostic gut relaxant, not a weight-loss or metabolic treatment, and the glucagon-receptor activation in obesity drugs is a separate, balanced use of the same receptor.
What's next
What we're watching.
Real-world results for nasal and ready-to-use glucagon, mini-dose glucagon for milder lows, dual-hormone (insulin plus glucagon) artificial-pancreas systems, and how glucagon-receptor activation is tuned in the dual and triple agonists.
Context
Why this is discussed.
Most people meet glucagon only inside the names of new obesity drugs, the GLP-1/glucagon dual agonists. But glucagon is a hormone in its own right, insulin's mirror image, and an approved emergency rescue for severe low blood sugar, now available needle-free as a nasal powder. Knowing what it actually does makes the dual and triple agonist drugs much easier to understand.
The evidence base
14 cited references.
Regulatory & labels3
Mylan Pharmaceuticals Inc. (FDA label) · 2024
Professional Complementary Health Formulas (FDA label) · 2026
A-S Medication Solutions (FDA label) · 2023
Indexed literature (PubMed)11
Iqbal A et al. · Best Pract Res Clin Endocrinol Metab · 2016
Kajani S et al. · Physiol Rev · 2024
Wewer Albrechtsen NJ et al. · Diabetologia · 2023
Blair HA · Drugs · 2021
Kalra S et al. · J Pak Med Assoc · 2019
Meijer E et al. · Presse Med · 1994
Kronfol MM et al. · Clin Pharmacol Ther · 2024
Kumar S et al. · Int J Pharm · 2024
Med Lett Drugs Ther · Med Lett Drugs Ther · 2019
Janah L et al. · Int J Mol Sci · 2019
Goodhart AL · Ann Pharmacother · 2023
Keep reading